Kairos Pharma, Ltd. (KAPA) Price & Analysis

Compare

129 Followers

KAPA Stock Chart & Stats

$0.80

-$0.43(-28.67%)

At close: Jan 08 4:00 PM EST

$0.80

-$0.43(-28.67%)

Day’s Range― - ―

52-Week Range$0.40 - $3.25

Previous CloseN/A

Volume680.77K

Average Volume (3M)1.08M

Market Cap

$16.76M

Enterprise ValueN/A

Total Cash (Recent Filing)$5.58M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.03

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.20

Shares Outstanding20,821,354

10 Day Avg. Volume532,234

30 Day Avg. Volume1,076,746

Financial Highlights & Ratios

PEG Ratio-0.19

Price to Book (P/B)3.61

Price to Sales (P/S)0.00

P/FCF Ratio-4.36

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

$4.00

Price Target Upside400.00% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trial SuccessPositive interim efficacy data from the ongoing Phase 2 trial of ENV-105 combined with Erleada in metastatic castration-resistant prostate cancer patients shows promising results, with a median progression-free survival exceeding 13 months.

Market OpportunityENV-105 could be used to improve or extend the efficacy of blockbuster drugs in their respective indications, providing a unique market opportunity.

Safety ProfilePositive safety data from the Phase 2 trial indicates no dose-limiting toxicities or unexpected adverse effects, highlighting a favorable safety profile for ENV-105.

Bears Say

Kairos Pharma, Ltd. News

Kairos Pharma’s Promising Clinical Developments and Strategic Focus Drive Buy Rating

Maxim Group analyst Jason McCarthy maintained a Buy rating on Kairos Pharma, Ltd. yesterday and set a price...

1M ago

KAPA

Kairos Pharma Approves RSUs and Cash Bonuses

Kairos Pharma, Ltd. ( ($KAPA) ) has issued an announcement. On October 8, 2025, Kairos Pharma, Ltd.‘s Compensation...

2M ago

KAPA

Promising Developments in Kairos Pharma’s Lead Candidate ENV-105 Drive Buy Rating

Maxim Group analyst Jason McCarthy has maintained their bullish stance on KAPA stock, giving a Buy rating on...

3M ago

KAPA

Kairos Pharma to Present at ESMO Congress 2025

Kairos Pharma, Ltd. ( ($KAPA) ) has provided an announcement. On October 7, 2025, Kairos Pharma announced its...

3M ago

KAPA

Promising Phase 2 Results and Safety Profile of ENV-105 Bolster Buy Rating for Kairos Pharma

Kairos Pharma, Ltd., the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis...

3M ago

KAPA

Kairos Pharma Reports Positive Phase 2 Trial Results

Kairos Pharma, Ltd. ( ($KAPA) ) has issued an update. On September 18, 2025, Kairos Pharma announced positive...

3M ago

KAPA

Kairos Pharma announces interim efficacy analysis of ENV105

Kairos Pharma (KAPA) announced efficacy data from its ongoing Phase 2 clinical trial of ENV105 in patients with...

3M ago

KAPA

Kairos Pharma’s Promising Developments and Positive Trial Data Reinforce Buy Recommendation

Analyst Jason McCarthy of Maxim Group reiterated a Buy rating on Kairos Pharma, Ltd., retaining the price target...

3M ago

KAPA

Kairos Pharma to Host KOL Event on Phase 2 Trial

Kairos Pharma, Ltd. ( ($KAPA) ) has shared an announcement. On September 11, 2025, Kairos Pharma announced it...

3M ago

KAPA

Kairos Pharma Presents Phase 1 Data at Conference

Kairos Pharma, Ltd. ( ($KAPA) ) has issued an announcement. On September 3, 2025, Kairos Pharma announced its...

4M ago

KAPA

Kairos Pharma: Promising Drug Pipeline and Upcoming Catalysts Drive Buy Rating

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on Kairos Pharma, Ltd.. The associated price...

4M ago

KAPA

Kairos Pharma management to meet with Maxim

Meeting to be held on August 6 hosted by Maxim. Published first on TheFly – the ultimate source...

5M ago

KAPA

Kairos Pharma announces positive safety results from Phase 2 ENV-105 trial

Kairos Pharma (KAPA) announced positive safety results from its ongoing Phase 2 clinical trial of ENV-105 in patients...

5M ago

KAPA

Kairos Pharma files to sell 16.29M shares of common stock for holders

06:05 EDT Kairos Pharma (KAPA) files to sell 16.29M shares of common stock for holders Published first on...

8M ago

KAPA

KAPA FAQ

What was Kairos Pharma, Ltd.’s price range in the past 12 months?

Kairos Pharma, Ltd. lowest stock price was $0.40 and its highest was $3.25 in the past 12 months.

What is Kairos Pharma, Ltd.’s market cap?

Kairos Pharma, Ltd.’s market cap is $16.76M.

When is Kairos Pharma, Ltd.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were Kairos Pharma, Ltd.’s earnings last quarter?

Currently, no data Available

Is Kairos Pharma, Ltd. overvalued?

According to Wall Street analysts Kairos Pharma, Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kairos Pharma, Ltd. pay dividends?

Kairos Pharma, Ltd. does not currently pay dividends.

What is Kairos Pharma, Ltd.’s EPS estimate?

Kairos Pharma, Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Kairos Pharma, Ltd. have?

Kairos Pharma, Ltd. has 20,821,354 shares outstanding.

What happened to Kairos Pharma, Ltd.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of Kairos Pharma, Ltd.?

Currently, no hedge funds are holding shares in KAPA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Kairos Pharma, Ltd.

Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.

KAPA Stock 12 Month Forecast

Average Price Target

$4.00

▲(400.00% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","5":"$5","-1":"-$1","0.5":"$0.5","3.5":"$3.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$4.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.5,2,3.5,5],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2024","6":"Apr<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.13,1.3507692307692307,1.5715384615384616,1.7923076923076922,2.013076923076923,2.233846153846154,2.4546153846153844,2.6753846153846155,2.896153846153846,3.1169230769230767,3.3376923076923077,3.5584615384615383,3.779230769230769,{"y":4,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.13,1.3507692307692307,1.5715384615384616,1.7923076923076922,2.013076923076923,2.233846153846154,2.4546153846153844,2.6753846153846155,2.896153846153846,3.1169230769230767,3.3376923076923077,3.5584615384615383,3.779230769230769,{"y":4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.13,1.3507692307692307,1.5715384615384616,1.7923076923076922,2.013076923076923,2.233846153846154,2.4546153846153844,2.6753846153846155,2.896153846153846,3.1169230769230767,3.3376923076923077,3.5584615384615383,3.779230769230769,{"y":4,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":2.46,"date":1719792000000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.46,"date":1722470400000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":2.46,"date":1725148800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.36,"date":1727740800000,"info":"<div class=\"mt2 colorgray-1\">\n          No historical consensus available\n      </div>","marker":{"enabled":true,"symbol":"circle"}},{"y":1.36,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.19,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.59,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.7,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.92,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.41,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.13,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >